Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of clostridium difficile toxins A and B and salmonella enterica serovar typhimurium flagellin in a mouse model of clostridium difficile disease

Infection and Immunity

Volumn 81, Issue 6, 2013, Pages 2190-2196

  Ghose, Chandrabali ^a   Verhagen, Janneke M ^a   Chen, Xinhua ^b   Yu, Jian ^a   Huang, Yaoxing ^a   Chenesseau, Olivia ^a,c   Kelly, Ciarán P ^b   Hoa, David D ^d  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SORBONNE UNIVERSITÉ   (France)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FLAGELLIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR 5; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SALMONELLA TYPHIMURIUM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CELL LINE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; FEMALE; FLAGELLIN; MICE; MICE, INBRED C57BL; PROTEIN SUBUNITS; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; TOLL-LIKE RECEPTOR 5; VACCINES, SYNTHETIC;

EID: 84877800051     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01074-12     Document Type: Article

References (38)

1. Bartlett JG. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
2. Mylonakis E, Ryan ET, Calderwood SB. 2001. Clostridium difficileassociated diarrhea: a review. Arch. Intern. Med. 161:525-533.
3. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263.
4. Jank T, Giesemann T, Aktories K. 2007. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17:15R-22R.
5. Jank T, Aktories K. 2008. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol. 16:222-229.
6. Kyne L, Warny M, Qamar A, Fatimi A, Wei JY, Lamont JT, Kelly CP. 1999. Natural immunity against Clostridium difficile toxin A protects against diarrhea and pseudomembranous colitis. Gastroenterology 116:A895.
7. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
8. Kyne L, Warny M, Qamar A, Kelly CP. 2000. High anti-toxin A antibody levels are associated with protection against recurrent Clostridium difficile diarrhea. Gastroenterology 118:A885.
9. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193.
10. Leav BA, Blair B, Leney M, Knauber M, Reilly CLowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D. 2010. T Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-969.
11. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
12. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713.
13. Giannasca PJ, Warny M. 2004. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848-856.
14. Ward SJ, Douce G, Dougan G, Wren BW. 1997. Delivery of non-toxic fragments of Clostridium difficile toxin A to the mucosal immune system. Rev. Med. Microbiol. 8:S34 -S36.
15. Ward SJ, Douce G, Dougan G, Wren BW. 1999. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin a from Clostridium difficile. Infect. Immun. 67:5124-5132.
16. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. 1999. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect. Immun. 67:2145-2152.
17. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. 2009. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 27:3598-3604.
18. van Duin D, Medzhitov R, Shaw AC. 2006. Triggering TLR signaling in vaccination. Trends Immunol. 27:49-55.
19. Jacchieri SG, Torquato R, Brentani RR. 2003. Structural study of binding of flagellin by Toll-like receptor 5. J. Bacteriol. 185:4243-4247.
20. Akira S, Takeda K, Kaisho T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-680.
21. Jarchum I, Liu M, Lipuma L, Pamer EG. 2011. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect. Immun. 79:1498-1503.
22. Chen XH, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding D, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992.
23. Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F, Calderwood SB, Kelly CP, Ryan ET. 2007. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect. Immun. 75:2826-2832.
24. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. 2004. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J. Med. Microbiol. 53:887-894.
25. Torres JF, Lyerly DM, Hill JE, Monath TP. 1995. Evaluation of formalininactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect. Immun. 63:4619-4627.
26. Tasteyre A, Barc MC, Karjalainen T, Dodson P, Hyde S, Bourlioux P, Borriello P. 2000. A Clostridium difficile gene encoding flagellin. Microbiology 146:957-966.
27. Bowman CC, Clements JD. 2001. Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect. Immun. 69:1528-1535.
28. Dickinson BL, Clements JD. 1995. Dissociation of Escherichia-Coli heatlabile enterotoxin adjuvanticity from Adp-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
29. Chong C, Friberg M, Clements JD. 1998. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. Vaccine 16:732-740.
30. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. 2008. Physical characterization of Clostridium difficile toxins and toxoids: effect of the formaldehyde crosslinking on thermal stability. J. Pharm. Sci. 97: 3735-3752.
31. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. 2008. Preformulation studies of Clostridium difficile toxoids A and B. J. Pharm. Sci. 97:4194-4207.
32. Foglia G, Shah S, Luxemburger C, Pietrobon PJ. 2012. Clostridium difficile: development of a novel candidate vaccine. Vaccine 30:4307-4309.
33. Fekety R, Silva J, Toshniwal R, Allo M, Armstrong J, Browne R, Ebright J, Rifkin G. 1979. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev. Infect. Dis. 1:386-397.
34. Brun P, Scarpa M, Grillo A, Palu G, Mengoli C, Zecconi A, Spigaglia P, Mastrantonio P, Castagliuolo I. 2008. Clostridium difficile TxAC314 and SLP-36kDa enhance the immune response toward a co-administered antigen. J. Med. Microbiol. 57:725-731.
35. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. 2011. Safety and immunogenicity of a recombinant M2e15 flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145-5152.
36. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. 2001. Safety and immunogenicity of oral inactivated wholecell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69:3581-3590.
37. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, Del Giudice G, Rappuoli R. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999. doi:10.1371/journal.pone.0006999.
38. Norton EB, Lawson LB, Freytag LC, Clements JD. 2011. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin. Vaccine Immunol. 18:546-551.